US9416184B2ActiveUtilityA1

Method of treating pruritus with IL-31 monoclonal antibodies

88
Assignee: ZYMOGENETICS INCPriority: Dec 7, 2007Filed: Mar 12, 2015Granted: Aug 16, 2016
Est. expiryDec 7, 2027(~1.4 yrs left)· nominal 20-yr term from priority
Inventors:Kent BondensgaardRoland Beckmann
A61P 43/00A61P 37/08A61P 29/00A61P 17/00A61P 17/14A61P 17/04C07K 2317/76C07K 2317/51C07K 16/244C07K 2317/52C07K 2317/56C07K 2317/24C12N 15/63C07K 2317/515C12N 5/10A61K 2039/505C07K 2317/92A61K 39/00114
88
PatentIndex Score
5
Cited by
276
References
28
Claims

Abstract

The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A method of treating pruritus in a mammal comprising administering to the mammal a therapeutically effective amount of a monoclonal antibody that specifically binds to human IL-31, wherein the monoclonal antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:44, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:26. 
     
     
       2. The method according to  claim 1 , wherein the monoclonal antibody comprises a human Fc domain. 
     
     
       3. The method according to  claim 2 , wherein the isotype of the human Fc domain is IgG1, IgG2, IgG3 or IgG4. 
     
     
       4. The method according to  claim 2 , wherein the isotype of the human Fc domain is IgG4. 
     
     
       5. The method according to  claim 4 , wherein the IgG4 human Fc domain has a serine to proline mutation at position 241 as determined by Kabat. 
     
     
       6. The method according to  claim 1 , wherein the heavy chain domain of the monoclonal antibody comprises the amino acid sequence of SEQ ID NO:47. 
     
     
       7. The method according to  claim 1 , wherein the light chain domain of the monoclonal antibody comprises the amino acid sequence of SEQ ID NO:46. 
     
     
       8. A method of treating pruritus in a mammal comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a monoclonal antibody that specifically binds to human IL-31 and a pharmaceutically acceptable carrier, wherein the monoclonal antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:44, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:26. 
     
     
       9. The method according to  claim 8 , wherein the monoclonal antibody comprises a human Fc domain. 
     
     
       10. The method according to  claim 9 , wherein the isotype of the human Fc domain is IgG1, IgG2, IgG3 or IgG4. 
     
     
       11. The method according to  claim 9 , wherein the isotype of the human Fc domain is IgG4. 
     
     
       12. The method according to  claim 11 , wherein the IgG4 human Fc domain has a serine to proline mutation at position 241 as determined by Kabat. 
     
     
       13. The method according to  claim 8 , wherein the heavy chain domain of the monoclonal antibody comprises the amino acid sequence of SEQ ID NO:47. 
     
     
       14. The method according to  claim 8 , wherein the light chain domain of the monoclonal antibody comprises the amino acid sequence of SEQ ID NO:46. 
     
     
       15. A method of treating a pruritic disease in a mammal comprising administering to the mammal a therapeutically effective amount of a monoclonal antibody that specifically binds to human IL-31, wherein the monoclonal antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:44, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:26, and wherein the pruritic disease is selected from the group consisting of atopic dermatitis, contact dermatitis, dermatitis, prurigo nodularis, eczema, vitiligo, alopecia aerata, acne rosacea, acne vulgaris and bullous pemphigoid. 
     
     
       16. The method according to  claim 15 , wherein the monoclonal antibody comprises a human Fc domain. 
     
     
       17. The method according to  claim 16 , wherein the isotype of the human Fc domain is IgG1, IgG2, IgG3 or IgG4. 
     
     
       18. The method according to  claim 16 , wherein the isotype of the human Fc domain is IgG4. 
     
     
       19. The method according to  claim 18 , wherein the IgG4 human Fc domain has a serine to proline mutation at position 241 as determined by Kabat. 
     
     
       20. The method according to  claim 15 , wherein the heavy chain domain of the monoclonal antibody comprises the amino acid sequence of SEQ ID NO:47. 
     
     
       21. The method according to  claim 15 , wherein the light chain domain of the monoclonal antibody comprises the amino acid sequence of SEQ ID NO:46. 
     
     
       22. A method of treating a pruritic disease in a mammal comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a monoclonal antibody that specifically binds to human IL-31 and a pharmaceutically acceptable carrier, wherein the monoclonal antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:44, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:26, and wherein the pruritic disease is selected from the group consisting of atopic dermatitis, contact dermatitis, dermatitis, prurigo nodularis, eczema, vitiligo, alopecia aerata, acne rosacea, acne vulgaris and bullous pemphigoid. 
     
     
       23. The method according to  claim 22 , wherein the monoclonal antibody comprises a human Fc domain. 
     
     
       24. The method according to  claim 23 , wherein the isotype of the human Fc domain is IgG1, IgG2, IgG3 or IgG4. 
     
     
       25. The method according to  claim 23 , wherein the isotype of the human Fc domain is IgG4. 
     
     
       26. The method according to  claim 25 , wherein the IgG4 human Fc domain has a serine to proline mutation at position 241 as determined by Kabat. 
     
     
       27. The method according to  claim 22 , wherein the heavy chain domain of the monoclonal antibody comprises the amino acid sequence of SEQ ID NO:47. 
     
     
       28. The method according to  claim 22 , wherein the light chain domain of the monoclonal antibody comprises the amino acid sequence of SEQ ID NO:46.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.